RiverVest is a leading venture capital firm building life science companies
to address significant unmet needs of patients and deliver consistently strong returns to investors.
/ RIVERVEST NEWS
Bluejay Therapeutics Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic Dysfunction – Associated Steatohepatitis (MASH) – 5/7/2025
FLEX Vessel Prep™ System FLEX FIRST AV Registry 6-Month Data and the Hamburg Vessel Prep Experience Prior to Angioplasty presented at Charing Cross Symposium – 4/23/2025
Biolinq Announces Close of $100M Series C Financing to Advance Its Biowearable Platform for Metabolic Health – 4/22/2025
Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG – 4/16/2025
Atlanta Therapeutics Publishes Preclinical Data Supporting Investigational RNAi Therapy for KCNT1-Related Epilepsy – 4/8/2025
Avalyn Pharma
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis – 4/1/2025
Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D – 3/26/2025
Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007 – 3/20/2025
VentureMed Strengthens Commercial Leadership and Expands Clinical Evidence
to Drive FLEX Vessel Prep™ System Growth – 3/12/2025
Wugen, Inc.
Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer – 2/26/2025
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments – 1/30/2025
Atalanta Therapeutics Closes Oversubscribed $97 Million Series B Financing to Advance Two RNAi Therapies for CNS Diseases to Clinical Trial – 1/28/2025
Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta- 1/21/2025
Alleviant Medical Secures $90 Million Financing to Expand Interventional Heart Failure Pivotal Trial Program – 1/14/2025
Novel Heart Failure Technology from Alleviant Medical Gains FDA Approval for New Pivotal Trial and Breakthrough Designation for Significant Patient Population – 1/7/2025
Subscribe to our newsletter